Latest Factor VII Stories
DEERFIELD, Ill., April 16, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported today that partner Baxter International Inc.
Landmark Lightings and Community Activities Honor People Affected by the Disorder WESTON, Mass., April 16, 2015 /PRNewswire/ -- In recognition of World Hemophilia Day,
rIX-FP Regulatory Submissions Now Made in EU and U.S.; Underscores CSL Behring's Legacy of Improving the Care for Patients with Bleeding Disorders KING OF PRUSSIA,
PLAINSBORO, N.J., March 26, 2015 /PRNewswire/ -- Novo Nordisk today announced the company will launch Novoeight(®) (Antihemophilic Factor [Recombinant]) in the United States for people living
DEERFIELD, Ill., Feb. 11, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) reported that partner Baxter International Inc.
CSL Behring Achieves Another Key Milestone in PROLONG-9FP, its Recombinant Factor IX Fusion Protein Development Program; Continues to Advance CSL Behring's Legacy of Improving Patient Well-Being
Researchmoz added new research report on Recombinant Coagulation Factors Pipeline Analysis to 2015 to its huge collection. Albany, NY (PRWEB) February 01, 2015
COPENHAGEN, Denmark and SEATTLE, Jan. 30, 2015 /PRNewswire/ -- Serendex Pharmaceuticals A/S (XOSL: SENDEX) and CMC Biologics, Inc. have today signed an exclusive agreement on Factor VIIa.
Marketresearchreports.biz has announced the addition of a new research study on the global and China blood product industry titled China Blood Product Industry Report 2014-2017 to its offering.
DUBLIN, January 27, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pfd99m/recombinant) has announced the addition of the "Recombinant
- An armed gangster.